Baron Funds Comments on Illumina Inc.

Author's Avatar
May 29, 2014

Shares of Illumina, Inc. (ILMN, Financial), the leading provider of next generation DNA sequencing instruments and consumables, rose 34% in the first quarter, driven by better than expected fourth quarter financial results, strong 2014 financial guidance, and the announcement of multiple new product introductions, including an ultra-high throughput sequencing platform that will be the first to sequence a full human genome for less than $1,000. We believe Illumina has further distanced itself from its competitors and holds an effective monopoly on DNA sequencing at a time when demand is accelerating.

From Baron Funds' first quarter 2014 commentary.